Health Care Equipment

Cutera

Cutera, Inc. Reaches Restructuring Agreement with Lenders to Reduce Nearly $400 Million in Debt

Cutera released FY2024 9 Months Earnings on November 7 After-Market (EST), with actual revenue of $105.67M and EPS of -4.31

Cutera released FY2024 Q3 earnings on November 7 After-Market (EST), actual revenue $32.50M (forecast $32.04M), actual EPS -1.94 (forecast -1.265)

Cutera to Release FY2024 Q3 Earnings on November 7, After-Market EST; Forecasted Revenue: 32.04 M USD, EPS: -1.265 USD

Cutera Q4 Revenue Exceeds Expectations

A SPAC III Acquisition

PicoCELA

Davis Commodities

Society Pass

ECD Automotive Design

Gauzy

Bristol-Myers Squibb Company

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Paranovus ENT Tech

Cue BioPharma

Delcath

Electromed

Abbott Laboratories

Intuitive Surgical

Boston Scientific

Stryker

IDEXX Labs

Edwards Lifesciences

Resmed

DexCom

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap